Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
Tommaso Susini,1 Barbara Berti,1 Carlo Carriero,1 Ketty Tavella,2 Jacopo Nori,3 Ermanno Vanzi,3 Cecilia Molino,1 Mariarosaria Di Tommaso,1 Marco Santini,1 Valeria Saladino,4 Simonetta Bianchi4 1Department of Health Science, Gynecology Section, 2Department of Health Science, Chemotherapy Section, Un...
Main Authors: | Susini T, Berti B, Carriero C, Tavella K, Nori J, Vanzi E, Molino C, Di Tommaso M, Santini M, Saladino V, Bianchi S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-11-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/topoisomerase-ii-alpha-and-tle3-as-predictive-markers-of-response-to-a-peer-reviewed-article-OTT |
Similar Items
-
Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer
by: Azra Rašić, et al.
Published: (2019-02-01) -
Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
by: Eun Kyo Joung, et al.
Published: (2021-01-01) -
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
by: Serena Di Cosimo, et al.
Published: (2019-01-01) -
Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
by: Qiu-Wen Tan, et al.
Published: (2017-03-01) -
Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
by: Zhipeng Wang, et al.
Published: (2018-07-01)